within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX04_Fludeoxyglucose18f;

model Fludeoxyglucose18f
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2e-06,
    adminDuration = 600,
    adminMass = 370 / 1000000,
    adminCount = 1,
    Vd = 0.00028000000000000003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00011999999999999999,
    k12 = 4.333333333333333e-06,
    k21 = 4.333333333333333e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fludeoxyglucose18f</td></tr><tr><td>ATC code:</td><td>V09IX04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>370</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.28</td><td>L</td></tr>
    <tr><td>clearance:</td><td>120</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fludeoxyglucose (18F) is a radiopharmaceutical analog of glucose used primarily in positron emission tomography (PET) imaging for the assessment of glucose metabolism in tissues, especially in oncology, cardiology, and neurology. It is approved and widely used today as a diagnostic agent, not as a therapeutic drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult humans after standard intravenous administration for PET imaging.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V09IX04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fludeoxyglucose18f;
